What is the clinical evidence from this study?

Study design: Cohort. Population: Hypertension (n=12169). Intervention: Non-high-density lipoprotein cholesterol (non-HDL-C) vs. Baseline non-HDL-C. Primary outcome: All-cause mortality (per 10 mg/dl increment above 158 mg/dl) (HR 1.03, 95% CI 1.01-1.05, p=0.013).

July 14, 2021Frontiers in Cardiovascular MedicineOpen Access

The U-Shaped Association of Non-High-Density Lipoprotein Cholesterol Levels With All-Cause and Cardiovascular Mortality Among Patients With Hypertension

Q: What are the key findings of this study?

Non-HDL-C exhibited a U-shaped association with mortality in hypertensive patients, with levels above 158 mg/dl increasing all-cause mortality risk by 3% per 10 mg/dl increment (HR 1.03).

Q: What does this research mean for the field?

Non-HDL-C exhibits a U-shaped association with mortality in hypertensive patients, with levels above 158 mg/dl increasing all-cause mortality risk by 3% per 10 mg/dl increment. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

View Full Paper

Ask AI

Bookmark

Key result

Non-HDL-C above 158 mg/dL linked to ~3% higher mortality per 10 mg/dL increment in hypertensive patients.

HR 1.03
95% CI 1.01-1.05
P=0.013
n=12,169

Why the study?

Non-HDL-C is a valuable routine blood lipid indicator, but its association with mortality in patients with hypertension remains uncertain.

Is there an association between non-HDL-C levels and all-cause or cardiovascular mortality in patients with hypertension?

Population

12,169 participants with hypertension from NHANES 1999 to 2014

Comparison

Non-HDL-C levels (<130, 130–159, 160–189, 190–219, and ≥220 mg/dl)

Follow-up

Average 92.5 months

Authors

QCQi ChengXinjiang Medical University XLXiaocong LiuXi'an Honghui Hospital CCChaolei ChenGuangdong Academy of Medical Sciences

Discussion

Member takes

Implication

May warrant caution with very low non-HDL-C in hypertension; hypothesis-generating and requires prospective validation.

Study Design

Type

Cohort (n=12,169)

Multicenter

Yes

Structured PICO

Is there an association between non-HDL-C levels and all-cause or cardiovascular mortality in patients with hypertension?

Population

12,169 participants with hypertension from the National Health and Nutrition Examination Surveys (1999-2014), mean age 57.27 ± 15.79 years, 47.52% male.

Intervention

Non-HDL-C levels (categorized as <130, 130–159, 160–189, 190–219, and ≥220 mg/dl)

Comparator

Different categories of non-HDL-C levels

Outcome

All-cause and cardiovascular mortalityhard clinical

Main Result

Effect estimate: HR 1.03 (95% CI 1.01-1.05)

p-value: p=0.013

In hypertensive patients, non-HDL-C exhibits a U-shaped association with mortality, suggesting both very low and high levels may be associated with increased risk.

Limitations

Smoking status and current medication treatment were self-reported, which may cause recall bias.
Blood lipid levels were only measured once at baseline and may have changed during follow-up.
Findings are applicable to the North American population and may not be generalizable to other regions.

Cite This Study

Cheng et al. (2021) conducted a cohort in Hypertension (n=12,169). Non-high-density lipoprotein cholesterol (non-HDL-C) vs. Baseline non-HDL-C was evaluated on All-cause mortality (per 10 mg/dl increment above 158 mg/dl) (HR 1.03, 95% CI 1.01-1.05, p=0.013). Non-HDL-C exhibited a U-shaped association with mortality in hypertensive patients, with levels above 158 mg/dl increasing all-cause mortality risk by 3% per 10 mg/dl increment (HR 1.03).

synapsesocial.com/papers/6a100c8296ccf432805fe96d https://doi.org/10.3389/fcvm.2021.707701

Topics

Hypertension management

View Full Paper

Ask AI

Bookmark

July 14, 2021Frontiers in Cardiovascular MedicineOpen Access

The U-Shaped Association of Non-High-Density Lipoprotein Cholesterol Levels With All-Cause and Cardiovascular Mortality Among Patients With Hypertension

View Full Paper

Ask AI

Bookmark

Key result

Non-HDL-C above 158 mg/dL linked to ~3% higher mortality per 10 mg/dL increment in hypertensive patients.

HR 1.03
95% CI 1.01-1.05
P=0.013
n=12,169

Why the study?

Non-HDL-C is a valuable routine blood lipid indicator, but its association with mortality in patients with hypertension remains uncertain.

Is there an association between non-HDL-C levels and all-cause or cardiovascular mortality in patients with hypertension?

Population

12,169 participants with hypertension from NHANES 1999 to 2014

Comparison

Non-HDL-C levels (<130, 130–159, 160–189, 190–219, and ≥220 mg/dl)

Follow-up

Average 92.5 months

Authors

QCQi ChengXinjiang Medical University XLXiaocong LiuXi'an Honghui Hospital CCChaolei ChenGuangdong Academy of Medical Sciences

Discussion

Member takes

Implication

May warrant caution with very low non-HDL-C in hypertension; hypothesis-generating and requires prospective validation.

Study Design

Type

Cohort (n=12,169)

Multicenter

Yes

Structured PICO

Is there an association between non-HDL-C levels and all-cause or cardiovascular mortality in patients with hypertension?

Population

12,169 participants with hypertension from the National Health and Nutrition Examination Surveys (1999-2014), mean age 57.27 ± 15.79 years, 47.52% male.

Intervention

Non-HDL-C levels (categorized as <130, 130–159, 160–189, 190–219, and ≥220 mg/dl)

Comparator

Different categories of non-HDL-C levels

Outcome

All-cause and cardiovascular mortalityhard clinical

Main Result

Effect estimate: HR 1.03 (95% CI 1.01-1.05)

p-value: p=0.013

In hypertensive patients, non-HDL-C exhibits a U-shaped association with mortality, suggesting both very low and high levels may be associated with increased risk.

Limitations

Smoking status and current medication treatment were self-reported, which may cause recall bias.
Blood lipid levels were only measured once at baseline and may have changed during follow-up.
Findings are applicable to the North American population and may not be generalizable to other regions.

Cite This Study

synapsesocial.com/papers/6a100c8296ccf432805fe96d https://doi.org/10.3389/fcvm.2021.707701

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Topics

Hypertension management

View Full Paper

Ask AI

Bookmark